Finkle B S, Jennison T A, Chinn D M, Ling W, Holmes E D
J Anal Toxicol. 1982 Mar-Apr;6(2):100-5. doi: 10.1093/jat/6.2.100.
The disposition of 1-alpha-acetylmethadol (LAAM) in plasma and urine was monitored by GC/CIMS following oral administration of 10 doses (0.73-1.5 mg/kg) over 42 days, to twelve human subjects. Plasma concentration-time course profiles fitted a two-compartment, first order kinetic model. Mean plasma t1/2 alpha for LAAM was 2.4 hours; t1/2 beta was 37.5 hours for the first dose and 46.8 hours for the last dose. The mean terminal half-life for nor-LAAM was 38.2 hours for first and 64.6 for last dose; for dinor-LAAM t1/2 beta was 168 hours, last dose. Drug accumulation occurred in some subjects, but within the study range, dosage was not related to maximum plasma levels nor to accumulation. In urine, the sum of LAAM, nor-LAAM, and dinor-LAAM represented 25% of the dose, and unconjugated methadol metabolites, 1.6-1.7%.
对12名受试者在42天内口服10剂(0.73 - 1.5毫克/千克)的1-α-乙酰美沙多(LAAM)后,通过气相色谱/化学电离质谱法(GC/CIMS)监测其在血浆和尿液中的处置情况。血浆浓度-时间过程曲线符合二室一级动力学模型。LAAM的平均血浆α半衰期为2.4小时;β半衰期第一剂为37.5小时,最后一剂为46.8小时。去甲LAAM的平均终末半衰期第一剂为38.2小时,最后一剂为64.6小时;二去甲LAAM的β半衰期最后一剂为168小时。部分受试者出现药物蓄积,但在研究范围内,剂量与最大血浆水平及蓄积均无关。在尿液中,LAAM、去甲LAAM和二去甲LAAM的总和占剂量的25%,未结合的美沙多代谢物占1.6 - 1.7%。